Metric 7 of 11 / Healthcare
Healthcare Costs (Prescription Drugs)
- Our grade
- F (editorial judgement)
- Promise
- Cut prescription drug out-of-pocket costs by 20%.
- Baseline
- $100 / month average out-of-pocket, as of 2024 (agreed baseline)
- Target
- $80 / month (-20%), by end of term
- Recorded at Year 1
- No measurable change to typical patient out-of-pocket costs
- Evidence as of
- October 2025 (Forbes analysis)
- Our verdict
- Signed an executive order, held the photo op, drug prices unchanged. The pharma lobby wrote him a thank you card.
- Check-in
- Year 1, published ; archive entry recorded
The grade and verdict are editorial judgement against the target locked in November 2024. Figures are as recorded in the Year 1 check-in, with the dates shown.
Sources and limits
Sources accompanying the Year 1 archive
- Executive Order 14297: Most-Favored-Nation Drug Pricing
- Forbes: Trump's Drug Price Initiative Has No Impact On Typical Patients
- Georgetown: Drug Pricing in the Era of Trump 2.0
Method and limits
Agreed measure: Track changes in pricing data from healthcare expenditure reports.
Year 1 method note: No dollar figure was recorded against the $100 baseline. The grade rests on analysis showing no measurable change for typical patients.
Archive note (Year 1): Recorded on 15/11/2026 from the Year 1 assessment published on 24/05/2026. Grades, figures and verdicts are as published that day, except two DOGE figures corrected on 15/11/2026: the verified share of DOGE's claim (published as about 30%) and the source of the $135 billion estimate (published as a CBS analysis). Source lists are as shown on the site on 15/11/2026, including links corrected or added after publication.
The locked register entry · The Year 1 check-in in full · Check-ins (JSON)
Dated corrections: Later evidence and method corrections to this archived assessment.
Receipt link: trumpscorecard.app/receipts/drug-prices